<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">31851566</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10.</ArticleTitle><Pagination><StartPage>1434</StartPage><EndPage>1440</EndPage><MedlinePgn>1434-1440</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2019.1691404</ELocationID><Abstract><AbstractText>Coxsackievirus A10 (CV-A10) has recently emerged as a major pathogen of hand, foot, and mouth disease in children worldwide. Currently no effective treatments are available; development of anti-CV-A10 vaccine is a most cost-effective way for CV-A10 prevention. Robust assay to measure neutralizing antibody (NtAb) titres elicited by vaccination would greatly prompt anti-CV-A10 vaccine development. Compare to the traditional neutralization assay based on inhibition of cytopathic effects (herein after referred to as cNT) which is time-consuming and labor-intensive, in this study we developed an efficient high-throughput neutralization antibody assay based on CV-A10 pseudoviruses (herein after referred to as pNT). In the pNT, anti-CV-A10 NtAb titre was negatively corresponded with the relative luminescent unit (RLU) produced by luciferase reporter gene incorporated in pseudovirus genome. As described in this study, the NtAb against CV-A10 could be detected within 10-16&#xa0;h, anti- CV-A10 NtAb in 67 human serum samples were measured in parallel with pNT and cNT assays, a good correlation (r&#xa0;=&#xa0;0.83,<i>p</i> &lt;&#xa0;.0001) and good agreement(97%) were shown between cNT and pNT, indicating that the pNT provides a rapid and convenient procedure for measuring NtAb production against anti-CV-A10 NtAb measurement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kelei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development Center, Minhai Biotechnology Co. Ltd , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Fangyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Department of Research, Lanzhou Institute of Biological Products Co. Ltd , Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Second Department of Research, Changchun Institute of Biological Products Co. Ltd , Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Second Department of Research, Lanzhou Institute of Biological Products Co. Ltd , Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Haifa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research and Development Center, Minhai Biotechnology Co. Ltd , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044482">Benzeneacetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010881">Piperidones</NameOfSubstance></Chemical><Chemical><RegistryNumber>16VY3TM7ZO</RegistryNumber><NameOfSubstance UI="C052091">antineoplaston A10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044482" MajorTopicYN="N">Benzeneacetamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010881" MajorTopicYN="N">Piperidones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A10</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">cytopathic effect</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">pseudovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31851566</ArticleId><ArticleId IdType="pmc">PMC7482785</ArticleId><ArticleId IdType="doi">10.1080/21645515.2019.1691404</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bian L, Gao F, Mao Q, Sun S, Wu X, Liu S, Yang X, Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Exp Rev Anti-infect Ther. 2019;17(4):233&#x2013;42. doi:10.1080/14787210.2019.1585242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2019.1585242</ArticleId><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji T, Guo Y, Huang W, Shi Y, Xu Y, Tong W, Yao W, Tan Z, Zeng H, Ma J, et al. The emerging sub-genotype C2 of CoxsackievirusA10 associated with hand, foot and mouth disease extensively circulating in mainland of China. Sci Rep. 2018;8:13357. doi:10.1038/s41598-018-31616-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31616-x</ArticleId><ArticleId IdType="pmc">PMC6127217</ArticleId><ArticleId IdType="pubmed">30190558</ArticleId></ArticleIdList></Reference><Reference><Citation>Munivenkatappa A, Yadav PD, Nyayanit DA, Majumdar TD, Sangal L, Jain S, Sinha DP, Shrivastava A, Mourya DT.. Molecular diversity of Coxsackievirus A10 circulating in the southern and northern region of India [2009&#x2013;17]. Infect Genet Evol. 2018;66:101&#x2013;10. doi:10.1016/j.meegid.2018.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2018.09.004</ArticleId><ArticleId IdType="pubmed">30217658</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Ding J, Cao J, Huang Q, Hong C, Yang B. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of Coxsackieviruses A10. J Med Virol. 2015;87:954&#x2013;60. doi:10.1002/jmv.v87.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.v87.6</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracho MA, Gonz&#xe1;lez-Candelas F, Valero A, C&#xf3;rdoba J, Salazar A. Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. Emerg Infect Dis. 2011;17:2223&#x2013;31. doi:10.3201/eid1712.110395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1712.110395</ArticleId><ArticleId IdType="pmc">PMC3311182</ArticleId><ArticleId IdType="pubmed">22172227</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada H, Wada M, Sato H, Yamaguchi Y, Tanji H, Kurokawa K, Kawanami T, Takahashi T, Kato T. Neuromyelitis optica preceded by hyperckemia and a possible association with coxsackie virus group a10 infection. Int Med. 2013;52:2665&#x2013;68. doi:10.2169/internalmedicine.52.1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.52.1042</ArticleId><ArticleId IdType="pubmed">24292760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Shukla D, Kumar R, Idris MZ, Jauhari P, Srivastava S, Dhole TN. Molecular identification of enteroviruses associated with aseptic meningitis in children from India. Arch Virol. 2013;158:211&#x2013;15. doi:10.1007/s00705-012-1476-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-012-1476-7</ArticleId><ArticleId IdType="pubmed">22975986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, Ye X, Liu Q, Zhou D, Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerging Microbes Infect. 2018;7:94. doi:10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Liu Q, Zhou Y, Ku Z, Wang L, Lan K, Ye X, Huang Z. Inactivated Coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34:5005&#x2013;12. doi:10.1016/j.vaccine.2016.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.033</ArticleId><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang C, Liu Q, Gong S, Geng L, Huang Z. A virus-like particle vaccine protects mice against Coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124&#x2013;30. doi:10.1016/j.antiviral.2018.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.016</ArticleId><ArticleId IdType="pubmed">29470994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Li J, Zhang X, Meng F, Zhou Y, Yao X, Gan Z, Zhu F. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6&#x2013;35 months. Hum Vaccines Immunother. 2016;12:916&#x2013;21. doi:10.1080/21645515.2015.1118595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1118595</ArticleId><ArticleId IdType="pmc">PMC4962943</ArticleId><ArticleId IdType="pubmed">26751765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, Bian L, Hao X, Hu Y, Yao X, Sun S, Chen P, Yang C, Du R, Li J, et al. Seroepidemiology of Coxsackievirus B5 in infants and children in Jiangsu Province, China. Hum Vaccines Immunother. 2017;14:74&#x2013;80. doi:10.1080/21645515.2017.1384107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1384107</ArticleId><ArticleId IdType="pmc">PMC5791574</ArticleId><ArticleId IdType="pubmed">29049009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SY, Gao F, Hu YL, Bian LL, Mao QY, Wu X, Li JX, Zhu FC, Wang JW, Liang ZL. Seroepidemiology of enterovirus d68 infection in infants and children in Jiangsu, China. J Infect. 2018;76:563&#x2013;69. doi:10.1016/j.jinf.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2018.02.003</ArticleId><ArticleId IdType="pubmed">29428227</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai WL, Xiong P, Zhang XY, Liu Z, Chen J, Zhou Y, Ye X, Zhang C. Recombinant virus-like particle presenting a newly identified Coxsackievirus A10 neutralization epitope induces protective immunity in mice. Antiviral Res. 2019;164:139&#x2013;46. doi:10.1016/j.antiviral.2019.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.02.016</ArticleId><ArticleId IdType="pubmed">30817941</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Manual for the virological investigation of poliomyelitis[M]. Geneva (Switzerland): World Health Organization; 2000.</Citation></Reference><Reference><Citation>Jiang Z, Liu G, Guo-Yang L, Sun M, Xu K, Ying Z, Wang J, Li X, Li C. A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum Vaccines Immunother. 2019;15:349&#x2013;57. doi:10.1080/21645515.2018.1526553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1526553</ArticleId><ArticleId IdType="pmc">PMC6422504</ArticleId><ArticleId IdType="pubmed">30273512</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhao Y, Wang C, Zheng X, Wang H, Gai W, Jin H, Yan F, Qiu B, Gao Y, et al. Packaging of Rift Valley fever virus pseudoviruses and establishment of a neutralization assay method. J Vet Sci. 2018;19:200&#x2013;06. doi:10.4142/jvs.2018.19.2.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.4142/jvs.2018.19.2.200</ArticleId><ArticleId IdType="pmc">PMC5879068</ArticleId><ArticleId IdType="pubmed">28693302</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P, Brendle S, Milici J, Camacho F, Zurlo J, Christensen N, Meyers C. Comparisons of VLP-based ELISA, neutralization assays with native HPV, and neutralization assays with PSV in detecting HPV antibody responses in HIV-infected women. J AIDS Clin Res. 2015;6:433. doi:10.4172/2155-6113.1000433.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-6113.1000433</ArticleId><ArticleId IdType="pmc">PMC4467835</ArticleId><ArticleId IdType="pubmed">26085957</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84:1439&#x2013;52. doi:10.1128/JVI.02108-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02108-09</ArticleId><ArticleId IdType="pmc">PMC2812321</ArticleId><ArticleId IdType="pubmed">19939925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Mao Q, Yao X, Chen P, Chen X, Shao J, Gao F, Yu X, Zhu F, Li R, et al. Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One. 2013;8:e64116. doi:10.1371/journal.pone.0064116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064116</ArticleId><ArticleId IdType="pmc">PMC3673970</ArticleId><ArticleId IdType="pubmed">23755115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao X, Chen P, Mao Q, Shao J, Lin H, Luo Z, Wu X, Liang Z. Establishment of a pseudovirus luciferase assay for the detection of coxsackievirus A16 neutralizing antibody. Chin J Viral Dis. 2016;6:6&#x2013;11.</Citation></Reference><Reference><Citation>Chen P, Wu X, Mao Q, Gao F, Hao X, Bian L, Zhu F, Li W, Xu M, Liang Z. A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3. J Virol Methods. 2016;232:1&#x2013;7. doi:10.1016/j.jviromet.2016.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2016.02.010</ArticleId><ArticleId IdType="pmc">PMC7113863</ArticleId><ArticleId IdType="pubmed">26947399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Wu X, Su Y, Hao X, Mao Q, Liang Z. Development of a pseudovirus based assay for measuring neutralizing antibodies against Coxsackievirus B5. J Virol Methods. 2017;246:21&#x2013;26. doi:10.1016/j.jviromet.2017.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2017.04.005</ArticleId><ArticleId IdType="pmc">PMC7113871</ArticleId><ArticleId IdType="pubmed">28435072</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Chen P, Gao F, Bian L, Sun S, Dong F, Hu Y, Mao Q, Jiang W, Wu X, et al. A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies. Hum Vaccin Immunother. 2018;14(12):3034&#x2013;40. doi:10.1080/21645515.2018.1504540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1504540</ArticleId><ArticleId IdType="pmc">PMC6343605</ArticleId><ArticleId IdType="pubmed">30060712</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muensch H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493&#x2013;97.</Citation></Reference><Reference><Citation>Bra&#x17e;d&#x17e;ionyt&#x117; J, Macas A. Bland&#x2013;altman analysis as an alternative approach for statistical evaluation of agreement between two methods for measuring hemodynamics during acute myocardial infarction. Medicina. 2006;43:3. doi:10.3390/medicina43030025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina43030025</ArticleId><ArticleId IdType="pubmed">17413249</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78&#x2013;85. doi:10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15:599&#x2013;606. doi:10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M, Chong P. Is a multivalent hand, foot and mouth disease vaccine feasible? Hum Vaccines Immunother. 2015;11:2688&#x2013;2674. doi:10.1080/21645515.2015.1049780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1049780</ArticleId><ArticleId IdType="pmc">PMC4685682</ArticleId><ArticleId IdType="pubmed">26009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Sun SY, Mao QY, Bian LL, Wu X, Zhu FC, Jiang CL, Gao F, Liang ZL. Seroepidemiology of Coxsackievirus A10 infection in infants and children: a prospective cohort study in Jiangsu, China. J Infect. 2018;77:158&#x2013;64. doi:10.1016/j.jinf.2018.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2018.04.005</ArticleId><ArticleId IdType="pubmed">29746947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Xu L, Zhu R, Yin Z, Lin Y, Hou W, Li S, He S, Cheng T, Xia N. Development of an efficient neutralization assay for Coxsackievirus A10. Appl Microbiol Biotechnol. 2019;103:1931&#x2013;38. doi:10.1007/s00253-018-09598-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-018-09598-7</ArticleId><ArticleId IdType="pubmed">30617817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>